Document Type : RESEARCH PAPER
Authors
1
Tehran University of Medical Sciences
2
Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran Department of Orthopedic Surgery, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran
3
Orthopedic Surgery Department, Faculty of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran
4
Mashhad university of medical sciences
5
Joint Reconstruction Research Center, Tehran University of Medical Sciences, Tehran, Iran
6
Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
7
Department of Orthopedic Surgery, Assistant Professor, Tehran University of Medical Science, Tehran, Iran
10.22038/abjs.2025.71614.3346
Abstract
Objectives:
This study aims to evaluate the safety and efficacy profile of aspirin as a standalone thromboprophylaxis (TP) treatment following elective total hip arthroplasty (THA). It also compares the primary and secondary outcomes for efficacy and safety, respectively, between aspirin and enoxaparin.
Methods:
A retrospective review of 2,107 patients who underwent primary or revision THA between 2011 and 2017 was conducted. Low-risk patients received aspirin (325 mg twice daily for 4 weeks), while high-risk patients received enoxaparin (4,000 units once daily for 2 weeks). Outcomes included symptomatic DVT or PE, hematoma, bleeding, infection, and 90-day mortality.
Results:
The incidence of symptomatic deep vein thrombosis (DVT) requiring treatment in the aspirin group was 0.10% (2/1,905), while no cases were observed in the enoxaparin group. The rate of fatal pulmonary embolism (PE) was 0.05% (1/1,905) in the aspirin group and 0.49% (1/202) in the enoxaparin group. Gastrointestinal (GI) bleeding occurred in 0.05% (1/1,905) of the aspirin group and 0.49% (1/202) of the enoxaparin group. The incidence of periprosthetic joint infection (PJI) was 0.15% (3/1,905) in the aspirin group compared to 0.49% (1/202) in the enoxaparin group.
Conclusion:
Aspirin, as a standalone TP agent, is at least as effective as potent anticoagulants like enoxaparin for patients undergoing elective THA, with comparable safety and efficacy profiles.
Keywords
Main Subjects
)